Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Nat Neurosci. 2013 Aug 4;16(9):1291–1298. doi: 10.1038/nn.3480

Figure 2. LM-4131 is an in vivo bioactive SSCI.

Figure 2

(a-d) Effects of increasing doses of LM-4131 on AEA, 2-AG, AA and PG in brain 2 hours after i.p. injection. (e-f) Combined data from multiple cohorts of mice showing average magnitude of LM-4131 effects on brain AEA and 2-AG levels as % vehicle treatment. (g-j) Effects of LM-4131, indomethancin, NS-398, and SC-560 on brain (g) AEA, (h) 2-AG, (i) AA, and (j) PG levels as a % of corresponding vehicle group. (k-n) Effects of LM-4131 on brain (k) AEA, (l) 2-AG, (m) AA, and (n) PG in WT and Ptgs2−/− mice. F and P values shown for one-way ANOVA, and p values for Dunnett's post hoc analysis show in (a-d); t-statistics and p values shown for unpaired two-tailed t-tests in (e-f and g-j; drug treatment vs. corresponding vehicle group); F and P values for genotype × LM-treatment interaction (G × T int) by two-way ANOVA, and p values for Sidak's multiple comparisons post hoc test shown in figures (k-l). n=number of mice per treatment group indicated in bars. Error bars represent S.E.M.